Short-Wavelength Light Sensitivity of Circadian, Pupillary, and Visual Awareness in Humans Lacking an Outer Retina

Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College London, London W6 8RF, United Kingdom.
Current Biology (Impact Factor: 9.92). 01/2008; 17(24):2122-8. DOI: 10.1016/j.cub.2007.11.034
Source: PubMed

ABSTRACT As the ear has dual functions for audition and balance, the eye has a dual role in detecting light for a wide range of behavioral and physiological functions separate from sight. These responses are driven primarily by stimulation of photosensitive retinal ganglion cells (pRGCs) that are most sensitive to short-wavelength ( approximately 480 nm) blue light and remain functional in the absence of rods and cones. We examined the spectral sensitivity of non-image-forming responses in two profoundly blind subjects lacking functional rods and cones (one male, 56 yr old; one female, 87 yr old). In the male subject, we found that short-wavelength light preferentially suppressed melatonin, reset the circadian pacemaker, and directly enhanced alertness compared to 555 nm exposure, which is the peak sensitivity of the photopic visual system. In an action spectrum for pupillary constriction, the female subject exhibited a peak spectral sensitivity (lambda(max)) of 480 nm, matching that of the pRGCs but not that of the rods and cones. This subject was also able to correctly report a threshold short-wavelength stimulus ( approximately 480 nm) but not other wavelengths. Collectively these data show that pRGCs contribute to both circadian physiology and rudimentary visual awareness in humans and challenge the assumption that rod- and cone-based photoreception mediate all "visual" responses to light.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Melatonin, secreted by the pineal gland during the night phase, is a regulator of the biological clock and sleep tendency. Totally blind subjects frequently report severe, periodic sleep problems, with 50%-75% of cases displaying non-24-hour sleep-wake disorder (N24HSWD) due to inability to synchronize with the environmental day-night cycle. Melatonin immediate-release preparations are reportedly effective in N24HSWD. Here, we studied the efficacy and safety of prolonged-release melatonin (PRM), a registered drug for insomnia, for sleep disorders in totally blind subjects living in normal social environments. The primary endpoint was demonstration of clinically meaningful effects on sleep duration (upper confidence interval [CI] limit >20 minutes whether significant or not) to allow early decision-making on further drug development in this indication. registry - NCT00972075. In a randomized, double-blind, placebo-controlled proof-of-principle study, 13 totally blind subjects had 2 weeks' placebo run-in, 6 weeks' randomized (1:1) PRM (Circadin(®)) or placebo nightly, and 2 weeks' placebo run-out. Outcome measures included daily voice recorded sleep diary, Clinical Global Impression of Change (CGIC), WHO-Five Well-being Index (WHO-5), and safety. Mean nightly sleep duration improved by 43 minutes in the PRM and 16 minutes in the placebo group (mean difference: 27 minutes, 95% CI: -14.4 to 69 minutes; P=0.18; effect size: 0.82) meeting the primary endpoint. Mean sleep latency decreased by 29 minutes with PRM over placebo (P=0.13; effect size: 0.92) and nap duration decreased in the PRM but not placebo group. The variability in sleep onset/offset and latency tended to decrease during PRM but not placebo treatment. The potentially beneficial effects of PRM persisted during the 2 weeks of discontinuation period, consistent with clock stabilizing effects. PRM was well-tolerated, adverse events were of mild or moderate severity and similar between PRM and placebo. Nightly use of PRM may potentially improve patient-reported sleep difficulties in totally blind individuals trying to adhere to normal social lifestyle. A larger study powered to demonstrate a statistically significant effect is warranted.
    Nature and Science of Sleep 7:13-23. DOI:10.2147/NSS.S71838
  • [Show abstract] [Hide abstract]
    ABSTRACT: In a previous research we have studied the effect of the stimulation of the retina, by pulsed LED's light of different wavelength, on the spectral density of the alpha rhythms of the electroencepha-logram [1] [2]. In conformity to our results and the recent discovery of a nonvisual pathway of light from the retina to the brain, we are induced to search for the effect of stimulation of the retina , with different wavelength, on the melatonin's secretion. We have, therefore, stimulated the retina with blue LED's light 470 nm and red LED's light 650 nm, and measured the melatonin's secretion in saliva by means of High Pressure Liquid Chromatography (HPLC). The results show that melatonin values are higher with long wavelength stimulation (red, 650 nm) to be confronted with short wavelength stimulation where the values are lower (blue, 470 nm), the difference being significant (***). Action spectrum of short wavelength, producing melatonin suppression, was already evidenced in vivo; it was also demonstrated that blue LED's light differentially modulated cell's survival and growth, inducing mitochondrial suppression in vitro. We speculate, therefore, that long wavelength light (red) produces photobiomodulation effect at the level of the retina and that this effect is the opposite of the effect produced by the short wavelength (blue). The molecular mechanism underlying both effects may be, we suppose, the activation (red) or depression (blue) of the mitochondrial cytochrome c oxidase activity at the level of the pool of the retina's ganglion cells.
    Neuroscience & Medicine 03/2015; 6(1):35-41. DOI:10.4236/nm.2015.61006
  • [Show abstract] [Hide abstract]
    ABSTRACT: The basic goal of this research is to determine the best combination of light wavelengths for use as a lighting countermeasure for circadian and sleep disruption during space exploration, as well as for individuals living on Earth. Action spectra employing monochromatic light and selected monochromatic wavelength comparisons have shown that short wavelength visible light in the blue-appearing portion of the spectrum is most potent for neuroendocrine, circadian, and neurobehavioral regulation. The studies presented here tested the hypothesis that broad spectrum, polychromatic fluorescent light enriched in the short wavelength portion of the visible spectrum is more potent for pineal melatonin suppression in healthy men and women. A total of 24 subjects were tested across three separate experiments. Each experiment used a within-subjects study design that tested eight volunteers to establish the full-range fluence-response relationship between corneal light irradiance and nocturnal plasma melatonin suppression. Each experiment tested one of three types of fluorescent lamps that differed in their relative emission of light in the short wavelength end of the visible spectrum between 400 and 500 nm. A hazard analysis, based on national and international eye safety criteria, determined that all light exposures used in this study were safe. Each fluence-response curve demonstrated that increasing corneal irradiances of light evoked progressively increasing suppression of nocturnal melatonin. Comparison of these fluence-response curves supports the hypothesis that polychromatic fluorescent light is more potent for melatonin regulation when enriched in the short wavelength spectrum. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Journal of Pineal Research 02/2015; DOI:10.1111/jpi.12221 · 7.81 Impact Factor

Full-text (3 Sources)

Available from
May 29, 2014